

February 17, 2023 | Issue 259

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



Healthcare regulatory news

In response to an October 2022 Executive Order, HHS directed the CMS Innovation Center to develop drug pricing models to: (1) increase access/affordability/adherence to widely-used generic drugs; (2) boost access to expensive cell and gene therapies; and, (3) incentivize timely completion of clinical trials for Accelerated Approval drugs.

CMS <u>proposed requiring skilled nursing facilities</u> to publicly report <u>additional</u> <u>ownership/management data</u>, including private equity and REIT ownership.

CMS told parties involved in surprise billing dispute resolution to <u>hold</u> <u>payment determinations</u> while it reviews a recent district court decision and updates guidance.

A Medicare advisory committee <u>recommended updating the Coverage with Evidence Development process</u>.

ONC <u>announced the first cohort of organizations</u> approved for onboarding as Qualified Health Information Networks to scale healthcare data interoperability.

An FDA advisory committee <u>unanimously recommended approving</u> an overthe-counter naloxone nasal spray... an <u>FDA-commissioned report</u> recommended FDA seek <u>additional authorities to regulate opioids and</u> <u>associated advertising</u>.

-



Healthcare law and policy news

CBO projected the <u>US will default on its debt between July and September</u>, absent raising or suspending the debt limit.

Elevance Health <u>completed acquisition</u> of BioPlus... Sanford and Fairview <u>delayed their merger until May</u>... CommonSpirit Health <u>will acquire five</u> <u>Steward hospitals</u> in Utah... Cigna <u>announced a corporate rebranding</u> and division into new business units... Doximity launched <u>a beta</u> ChatGPT <u>tool to streamline provider administrative</u> tasks... Albertsons <u>launched a digital health</u> <u>app</u> to integrate pharmacy, nutrition, virtual care, and wellness services.

JAMA studies found: (1) employer-sponsored plans pay more than Medicare for top-spend and top-use physician-administered drugs; (2) mean daily out-of-pocket buprenorphine costs fell from 2015 (\$4.79) to 2020 (\$1.91), with payer costs varying widely from \$0.10 (Medicaid) to \$8.44 (self-pay patients); and, (3) 10% of FDA-approved drugs from 2018-2021 were based on studies with null findings for at least one primacy efficacy endpoint...

Duke researchers found 11 of 37 contacted data brokers were willing/able to sell mental health information about customers, often with little effort to hide personal information.

CFPB <u>reported</u> the number of people with medical debt <u>declined 17.9%</u> (8.2M) between 2020 and 2022.

National Academies <u>recommended HHS and VA create an innovation center</u> to promulgate "whole health" best practices.

Senate Committees held hearings on \underline{PBM} $\underline{oversight}$ and the $\underline{healthcare}$ $\underline{workforce}.$

--



Special Section: COVID-19, Other Respiratory Illnesses, and mpox News

The Biden Administration is considering <u>a plan to continue making COVID-19 vaccines</u>, tests, and treatments free for uninsured individuals into 2024, even as the public health emergency (PHE) declaration ends in May; meanwhile, Moderna announced it will <u>continue to make its COVID-19 vaccine available to individuals</u> at no cost, regardless of insurance stance, after the PHE ends... AAFP urged the Biden Administration <u>to publish a "comprehensive plan"</u> for ending the public health emergency (PHE).

Novavax will sell 1.5M more doses of its COVID-19 vaccine to the federal government.

House Republicans <u>began investigations into the origins of COVID-19</u> by requesting documents and testimony from current and former Biden Administration officials.

A *Lancet* study found that people who previously had COVID-19 had an 88% lower risk of hospitalization or death from another infection for at least 10 months, as compared to someone who had never been infected... A *JAMA* study found the overall risk of new-onset type 2 diabetes after COVID-19 infection was about 2.1%; however, those who were vaccinated had a lower risk (1%) than those who were unvaccinated (2.7%).

NIH is <u>studying Shionogi's investigational antiviral</u> for hospitalized COVID-19 patients.

The World Health Organization announced that the mpox outbreak remains an Emergency of International Concern... FDA granted emergency use authorization to the first point-of-care mpox test.





Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.